Research Progress in Clinical Treatment of Ovarian Cancer

doi:10.12280/gjfckx.20210103

Abstract

Abstract:

Ovarian cancer is a malignant tumor of the female reproductive system with the highest mortality rate. The early clinical symptoms of the disease are not obvious, and most of them are in the advanced stage at the time of consultation. In addition, due to recurrence and chemotherapy resistance, the prognosis is poor. It seriously threatens women′s life and health, which leads to arduous challenges in the clinical treatment of ovarian cancer. The traditional treatment of ovarian cancer is surgical treatment plus adjuvant chemotherapy. In recent years, with the improvement of surgical methods, the continuous improvement of chemotherapy regimens and the application of targeted drugs, the treatment of ovarian cancer has been continuously enriched. Although it has improved the prognosis of ovarian cancer to a certain extent, its overall survival rate is still poor. In addition, immunotherapy can take advantage of the autoimmune system. In recent years, it has received extensive attention in the treatment of ovarian cancer, but its clinical application still needs to be explored in depth. Therefore, further optimizing the treatment of ovarian cancer, increasing the survival rate of patients and improving their prognosis are the most difficult points in the treatment of ovarian cancer. The current status and latest progress of clinical treatment of ovarian cancer are reviewed, in order to provide new ideas for the treatment of ovarian cancer and further improve its prognosis.

Key words: Ovarian neoplasms, Gynecologic surgical procedures, Antineoplastic combined chemotherapy protocols, Molecular targeted therapy, Poly(ADP-ribose) polymerase inhibitors, Immunotherapy

CHU Hui-hui, LIU Qian. Research Progress in Clinical Treatment of Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 443-447.

References 35

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. doi: 10.3322/caac.21590. doi: 10.3322/caac.21590
[2]	Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer[J]. N Engl J Med, 2018, 379(26):2495-2505. doi: 10.1056/NEJMoa1810858. doi: 10.1056/NEJMoa1810858
[3]	Coleman RL, Fleming GF, Brady MF, et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer[J]. N Engl J Med, 2019, 381(25):2403-2415. doi: 10.1056/NEJMoa1909707. doi: 10.1056/NEJMoa1909707
[4]	van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer[J]. N Engl J Med, 2018, 378(3):230-240. doi: 10.1056/NEJMoa1708618. doi: 10.1056/NEJMoa1708618
[5]	Rocconi RP, Grosen EA, Ghamande SA, et al. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Oncol, 2020, 21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7. doi: 10.1016/S1470-2045(20)30533-7
[6]	Facer B, Wang F, Grijalva CG, et al. Survival outcomes for robotic-assisted laparoscopy versus traditional laparoscopy in clinical stage I epithelial ovarian cancer[J]. Am J Obstet Gynecol, 2020, 222(5):474.e1-e12. doi: 10.1016/j.ajog.2019.10.104. doi: 10.1016/j.ajog.2019.10.104
[7]	佘宇佳, 叶明侠, 孟元光. 机器人、腹腔镜与开腹手术治疗卵巢癌的疗效比较[J]. 解放军医学院学报, 2020, 41(4):320-323. doi: 10.3969/j.issn.2095-5227.2020.04.002. doi: 10.3969/j.issn.2095-5227.2020.04.002
[8]	Nishio S, Ushijima K. Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer[J]. Jpn J Clin Oncol, 2020, 50(4):379-386. doi: 10.1093/jjco/hyaa015. doi: 10.1093/jjco/hyaa015 pmid: 32083282
[9]	Makar AP, Tropé CG, Tummers P, et al. Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer[J]. Oncologist, 2016, 21(6):745-754. doi: 10.1634/theoncologist.2015-0239. doi: 10.1634/theoncologist.2015-0239 pmid: 27009938
[10]	Onda T, Satoh T, Saito T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602[J]. Eur J Cancer, 2016, 64:22-31. doi: 10.1016/j.ejca.2016.05.017. doi: 10.1016/j.ejca.2016.05.017
[11]	Harter P, Sehouli J, Lorusso D, et al. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms[J]. N Engl J Med, 2019, 380(9):822-832. doi: 10.1056/NEJMoa1808424. doi: 10.1056/NEJMoa1808424
[12]	Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(8):896-909. doi: 10.6004/jnccn.2019.0039. doi: 10.6004/jnccn.2019.0039
[13]	Sehouli J, Grabowski JP. Surgery in recurrent ovarian cancer[J]. Cancer, 2019, 125(Suppl 24):4598-4601. doi: 10.1002/cncr.32511. doi: 10.1002/cncr.32511
[14]	Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine[J]. CA Cancer J Clin, 2019, 69(4):280-304. doi: 10.3322/caac.21559. doi: 10.3322/caac.21559
[15]	Bartels HC, Rogers AC, Postle J, et al. Morbidity and mortality in women with advanced ovarian cancer who underwent primary cytoreductive surgery compared to cytoreductive surgery for recurrent disease: a meta-analysis[J]. Pleura Peritoneum, 2019, 4(2):20190014. doi: 10.1515/pp-2019-0014. doi: 10.1515/pp-2019-0014 pmid: 31417960
[16]	Coleman RL, Spirtos NM, Enserro D, et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer[J]. N Engl J Med, 2019, 381(20):1929-1939. doi: 10.1056/NEJMoa1902626. doi: 10.1056/NEJMoa1902626
[17]	Buechel M, Herzog TJ, Westin SN, et al. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option[J]. Ann Oncol, 2019, 30(5):721-732. doi: 10.1093/annonc/mdz104. doi: S0923-7534(19)31176-7 pmid: 31987339
[18]	Onda T, Satoh T, Ogawa G, et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial[J]. Eur J Cancer, 2020, 130:114-125. doi: 10.1016/j.ejca.2020.02.020. doi: 10.1016/j.ejca.2020.02.020
[19]	Vergote I, Coens C, Nankivell M, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials[J]. Lancet Oncol, 2018, 19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. doi: S1470-2045(18)30566-7 pmid: 30413383
[20]	刘晓峰, 李玮, 佟芳. TC和PC化疗方案在晚期卵巢癌术后患者中的效果及安全性比较[J]. 医学综述, 2019, 25(21):4340-4344. doi: 10.3969/j.issn.1006-2084.2019.21.035. doi: 10.3969/j.issn.1006-2084.2019.21.035
[21]	Bartos A, Bartos D, Herdean A, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC). Mechanisms of action and the role of HIPEC in the treatment of peritoneal carcinomatosis[J]. Ann Ital Chir, 2018, 89:513-527.
[22]	Ghirardi V, Ronsini C, Trozzi R, et al. Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience[J]. Cancer, 2020, 126(24):5256-5262. doi: 10.1002/cncr.33167. doi: 10.1002/cncr.33167
[23]	Zhang Y, Dong Y, Fu H, et al. Multifunctional tumor-targeted PLGA nanoparticles delivering Pt(IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance[J]. Biomaterials, 2021, 269:120478. doi: 10.1016/j.biomaterials.2020.120478. doi: 10.1016/j.biomaterials.2020.120478
[24]	Xiao Y, Lin FT, Lin WC. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer[J]. Proc Natl Acad Sci U S A, 2021, 118(3):e2015808118. doi: 10.1073/pnas.2015808118. doi: 10.1073/pnas.2015808118
[25]	Mukherjee A, Huynh V, Gaines K, et al. Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin[J]. Cancer Res, 2019, 79(13):3185-3191. doi: 10.1158/0008-5472.CAN-19-0542. doi: 10.1158/0008-5472.CAN-19-0542 pmid: 31061066
[26]	Lee J, Cho YJ, Lee JW, et al. KSP siRNA/paclitaxel-loaded PEGylated cationic liposomes for overcoming resistance to KSP inhibitors: Synergistic antitumor effects in drug-resistant ovarian cancer[J]. J Control Release, 2020, 321:184-197. doi: 10.1016/j.jconrel.2020.02.013. doi: 10.1016/j.jconrel.2020.02.013
[27]	明茗, 辛妮, 张静静. 新辅助化疗与肿瘤减灭术治疗卵巢癌疗效和安全性的系统评价[J]. 中国计划生育和妇产科, 2020, 12(11):36-40. doi: 10.3969/j.issn.1674-4020.2020.11.11. doi: 10.3969/j.issn.1674-4020.2020.11.11
[28]	Min A, Im SA. PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation[J]. Cancers(Basel), 2020, 12(2):394. doi: 10.3390/cancers12020394. doi: 10.3390/cancers12020394
[29]	Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what's next after PARP inhibitors?[J]. Nat Rev Clin Oncol, 2018, 15(9):564-576. doi: 10.1038/s41571-018-0055-6. doi: 10.1038/s41571-018-0055-6 pmid: 29955114
[30]	Blessing C, Mandemaker IK, Gonzalez-Leal C, et al. The Oncogenic Helicase ALC1 Regulates PARP Inhibitor Potency by Trapping PARP2 at DNA Breaks[J]. Mol Cell, 2020, 80(5):862-875.e6. doi: 10.1016/j.molcel.2020.10.009. doi: 10.1016/j.molcel.2020.10.009
[31]	Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer[J]. Ann Oncol, 2019, 30(4):551-557. doi: 10.1093/annonc/mdz018. doi: S0923-7534(19)31114-7 pmid: 31987271
[32]	Pfisterer J, Shannon CM, Baumann K, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. doi: S1470-2045(20)30142-X pmid: 32305099
[33]	Zhao Y, Lee CK, Lin CH, et al. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways[J]. Immunity, 2019, 51(6):1059-1073.e9. doi: 10.1016/j.immuni.2019.11.003. doi: 10.1016/j.immuni.2019.11.003
[34]	Balança CC, Scarlata CM, Michelas M, et al. Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies[J]. Cancer Immunol Res, 2020, 8(7):869-882. doi: 10.1158/2326-6066.CIR-19-0855. doi: 10.1158/2326-6066.CIR-19-0855
[35]	Komura N, Mabuchi S, Shimura K, et al. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer[J]. Cancer Immunol Immunother, 2020, 69(12):2477-2499. doi: 10.1007/s00262-020-02628-2. doi: 10.1007/s00262-020-02628-2